Kiniksa Pharmaceuticals International Plc (KNSA)

03:17 AM

Taking on analysts’ expectations and winning: Kiniksa Pharmaceuticals International Plc (KNSA) - SETE News

03:17 AM

07:22 AM

Citigroup Initiates Coverage on Kiniksa Pharmaceuticals International With Buy Rating, $40 Price Target - Marketscreener.com

07:22 AM

Mar 12, 2025

Kiniksa Pharmaceuticals COO sells shares worth $261,333 - Investing.com

Mar 12, 2025

Mar 12, 2025

Kiniksa Pharmaceuticals COO sells shares worth $261,333 By Investing.com - Investing.com UK

Mar 12, 2025

Mar 07, 2025

Deeper Dive: Understanding Kiniksa Pharmaceuticals International Plc (KNSA) Through its Various Ratios - The Dwinnex

Mar 07, 2025

Mar 06, 2025

Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst - Benzinga

Mar 06, 2025

Mar 06, 2025

Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best UK Growth Stock to Buy Now? - Insider Monkey

Mar 06, 2025

Mar 06, 2025

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by Rhumbline Advisers - Defense World

Mar 06, 2025

Mar 05, 2025

New York State Common Retirement Fund Has $302,000 Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - Defense World

Mar 05, 2025

Mar 05, 2025

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Sees Large Increase in Short Interest - Defense World

Mar 05, 2025

Mar 02, 2025

Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best Small Cap Pharma Stocks to Buy Now? - Insider Monkey

Mar 02, 2025

Mar 02, 2025

Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best Small Cap Pharma Stock to Buy Now? - Insider Monkey

Mar 02, 2025

Feb 28, 2025

12 Best Small Cap Pharma Stocks to Buy Now - Insider Monkey

Feb 28, 2025

Feb 28, 2025

Decoding Kiniksa Pharmaceuticals International PLC (KNSA): A Str - GuruFocus.com

Feb 28, 2025

Feb 27, 2025

Kiniksa Pharmaceuticals Shifts Strategic Focus with Key Agreement Terminations and 2024 Financial Results - Defense World

Feb 27, 2025

Feb 26, 2025

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 26, 2025

Feb 25, 2025

Kiniksa Pharmaceuticals Q4 2024 Earnings: Revenue at $122.5M, Mi - GuruFocus.com

Feb 25, 2025

Feb 25, 2025

Kiniksa issues updates on abiprubart, KPL-387, mavrilimumab - MSN

Feb 25, 2025

Feb 25, 2025

Big Pipeline Updates From Kiniksa Pharmaceuticals (NASDAQ:KNSA) - Seeking Alpha

Feb 25, 2025

Feb 25, 2025

Kiniksa to launch Phase 2/3 trial for heart drug KPL-387 - Investing.com India

Feb 25, 2025

Feb 25, 2025

Kiniksa Pharmaceuticals Swings to Q4 Loss, Revenue Increases -February 25, 2025 at 08:20 am EST - Marketscreener.com

Feb 25, 2025

Feb 25, 2025

Kiniksa to launch Phase 2/3 trial for heart drug KPL-387 By Investing.com - Investing.com South Africa

Feb 25, 2025

Feb 25, 2025

Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q4 Total Revenue $122.5M, vs. FactSet Est of $123.4M - Marketscreener.com

Feb 25, 2025

Feb 25, 2025

Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q4 Net Loss $-0.12 a Share, vs. FactSet Est of $-0.06 Loss - Marketscreener.com

Feb 25, 2025

Feb 25, 2025

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution - The Manila Times

Feb 25, 2025

Feb 25, 2025

Kiniksa Pharmaceuticals Reports Strong Q4 2024 Financials with ARCALYST Revenue of $417 Million and Anticipates 2025 Sales Growth - Nasdaq

Feb 25, 2025

Feb 25, 2025

Kiniksa Pharmaceuticals Announces Development of KPL-387 in - GlobeNewswire

Feb 25, 2025

Feb 25, 2025

Can Kiniksa's 79% Revenue Surge Continue as Company Shifts Pipeline Focus? - StockTitan

Feb 25, 2025

Feb 25, 2025

Can Kiniksa's New Pericarditis Drug Build on Its $800M ARCALYST Success? - StockTitan

Feb 25, 2025

Feb 24, 2025

KNSAKiniksa Pharmaceuticals International, plc Latest Stock News & Market Updates - StockTitan

Feb 24, 2025

Feb 21, 2025

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 - GlobeNewswire

Feb 21, 2025

Feb 14, 2025

Kiniksa Pharmaceuticals COO Tessari Eben sells $273,980 in shares - MSN

Feb 14, 2025

Feb 14, 2025

Kiniksa Pharmaceuticals COO sells shares worth $273,980 - MSN

Feb 14, 2025

Feb 13, 2025

Kiniksa Pharmaceuticals: Strong Improvement In Arcalyst Revenue, But Risks Remain - Seeking Alpha

Feb 13, 2025

Feb 13, 2025

Kiniksa Pharmaceuticals COO sells shares worth $273,980 By Investing.com - Investing.com Canada

Feb 13, 2025

Feb 07, 2025

Kiniksa Pharmaceuticals International Plc (KNSA) Stock: Tracking the Weekly Performance - The News Heater

Feb 07, 2025

Feb 06, 2025

Is Kiniksa Pharmaceuticals International Plc (KNSA) a opportunity to investors? - US Post News

Feb 06, 2025

Feb 05, 2025

Keeping an Eye on Kiniksa Pharmaceuticals International Plc (KNSA) After Insider Trading Activity - Knox Daily

Feb 05, 2025

Feb 04, 2025

Stock Market Recap: Kiniksa Pharmaceuticals International Plc (KNSA) Concludes at 18.88, a -3.67 Surge/Decline - The Dwinnex

Feb 04, 2025

Jan 28, 2025

Exploring High Growth Tech Stocks in the United States - Simply Wall St

Jan 28, 2025

Jan 20, 2025

Kiniksa Pharmaceuticals Reports Strong 2024 Financial Results and Provides 2025 Revenue Guidance - Defense World

Jan 20, 2025

Jan 16, 2025

Kiniksa Pharmaceuticals COO Tessari Eben sells shares worth $255,413 - Investing.com India

Jan 16, 2025

Jan 14, 2025

Evolving Landscape of Cardiology Segment: Key Market Insights of Latest Published Rare Cardiovascular Diseases Report — Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy | DelveInsight - GlobeNewswire Inc.

Jan 14, 2025

Jan 13, 2025

Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance - The Manila Times

Jan 13, 2025

Jan 13, 2025

Kiniksa Pharmaceuticals Reports Preliminary 2024 Net - GlobeNewswire

Jan 13, 2025

Jan 13, 2025

Kiniksa's ARCALYST Soars 79% to $416M in 2024, Projects Strong 2025 Growth to $580M - StockTitan

Jan 13, 2025

Jan 06, 2025

Kiniksa Pharmaceuticals to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan

Jan 06, 2025

Jan 06, 2025

Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire

Jan 06, 2025

Dec 18, 2024

Kiniksa Pharmaceuticals COO Tessari Eben sells shares worth $470k - Investing.com

Dec 18, 2024